Adlai Nortye Ltd.
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E recept… Read more
Adlai Nortye Ltd. (N2U0) - Total Assets
Latest total assets as of December 2024: €71.27 Million EUR
Based on the latest financial reports, Adlai Nortye Ltd. (N2U0) holds total assets worth €71.27 Million EUR as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Adlai Nortye Ltd. - Total Assets Trend (2021–2024)
This chart illustrates how Adlai Nortye Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Adlai Nortye Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Adlai Nortye Ltd.'s total assets of €71.27 Million consist of 89.9% current assets and 10.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 85.5% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €40.00K | 0.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Adlai Nortye Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Adlai Nortye Ltd.'s current assets represent 89.9% of total assets in 2024, a decrease from 94.6% in 2021.
- Cash Position: Cash and equivalents constituted 85.5% of total assets in 2024, up from 48.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 0.1% of total assets.
Adlai Nortye Ltd. Competitors by Total Assets
Key competitors of Adlai Nortye Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Adlai Nortye Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Adlai Nortye Ltd. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Adlai Nortye Ltd. is currently not profitable relative to its asset base.
Adlai Nortye Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.41 | 1.85 | - |
| Quick Ratio | 1.41 | 1.85 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | €18.70 Million | € 45.97 Million | - |
Adlai Nortye Ltd. - Advanced Valuation Insights
This section examines the relationship between Adlai Nortye Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.61 |
| Asset Growth Rate (YoY) | -45.3% |
| Total Assets | €71.27 Million |
| Market Capitalization | $43.18 Million USD |
Valuation Analysis
Below Book Valuation: The market values Adlai Nortye Ltd.'s assets below their book value (0.61 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Adlai Nortye Ltd.'s assets decreased by 45.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Adlai Nortye Ltd. (2021–2024)
The table below shows the annual total assets of Adlai Nortye Ltd. from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €71.27 Million | -45.26% |
| 2023-12-31 | €130.19 Million | +79.34% |
| 2022-12-31 | €72.59 Million | -44.87% |
| 2021-12-31 | €131.69 Million | -- |